Litcius/Paper detail

Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials

Paschalis Karakasis, Dimitrios Patoulias, Konstantinos Pamporis, Panagiotis Stachteas, Konstantinos I. Bougioukas, Aleksandra Klisić, Nikolaos Fragakis, Manfredi Rizzo

2023Metabolism60 citationsDOI

Topics & Concepts

MedicineCochrane LibraryInternal medicineOdds ratioAdverse effectRandomized controlled trialMeta-analysisType 2 diabetesHypoglycemiaSubgroup analysisType 2 Diabetes MellitusDiabetes mellitusEndocrinologyInsulinDiabetes Treatment and ManagementBariatric Surgery and OutcomesPancreatic function and diabetes
Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials | Litcius